The apoptotic effect and associated signalling of HSP90 inhibitor 17-DMAG in hepatocellular carcinoma cells

Cell Biology International

Volumn 36, Issue 10, 2012, Pages 893-899

  Leng, Ai Min ^a   Liu, Ting ^a   Yang, Jing ^a   Cui, Jian Fang ^a   Li, Xiu Hua ^a   Zhu, Ya Nan ^a   Xiong, Ting ^a   Zhang, Guiying ^a   Chen, Yuxiang ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

17 DMAG; Cisplatin; Heat shock protein 90; Hepatocellular carcinoma

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ALVESPIMYCIN; CISPLATIN; CYCLIN D1; FLUORESCEIN ISOTHIOCYANATE; HEAT SHOCK PROTEIN 90; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOCORTIN 5; PROPIDIUM IODIDE; PROTEIN P53; SURVIVIN;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CARCINOMA CELL; CELL PROLIFERATION; CELL STRAIN HEPG2; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOQUINONES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; CYCLIN D1; HSP90 HEAT-SHOCK PROTEINS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LACTAMS, MACROCYCLIC; LIVER NEOPLASMS; NF-KAPPA B; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84867180781     PISSN: 10656995     EISSN: 10958355     Source Type: Journal    
DOI: 10.1042/CBI20110473     Document Type: Article

References (37)

1. Ades S. Adjuvant chemotherapy for colon cancer in the elderly: moving from evidence to practice. Oncology 2009;23:162-7.
2. Ai A, Yin L, Zhou X, Zhu D, Yu Y, Feng Y. Inhibition of surviving reduces cell proliferation and induces apoptosis in human endometrial cancer. Cancer 2006;107:746-56.
3. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-21.
4. Ayrault O, Godeny MD, Dillon C, Zindy F, Fitzgerald P, Roussel MF et al. Inhibition of Hsp90 via 17-DMAG induces apoptosis in a p53-dependent manner to prevent medulloblastoma. Proc Natl Acad Sci USA 2009;106:17039.
5. Babchia N. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf down-regulation in WT B-Raf-expressing uveal melanoma cell lines. IOVS 2008;49:6.
6. Chen G, Cao P, Goeddel DV. TNF-induced recruitment and activation of the IKK complex require Cdc37 and Hsp90. Mol Cell 2002;9:401-10.
7. Cheung CH, Chen HH, Cheng LT, Lyu KW, Kanwar JR, Chang JY. Targeting Hsp90 with small molecule inhibitors induces the overexpression of the anti-apoptotic molecule, survivin, in human A549, HONE-1 and HT-29 cancer cells. Mol Cancer 2010;9:77.
8. Egorin MJ, Lagattuta TF, Hamburger DR, Covey JM, White KD, Musser SM et al. Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats. Cancer Chemother Pharmacol 2002;49:7-19.
9. Eiseman JL, Lan J, Lagattuta TF, Hamburger DR, Joseph E, Covey JM et al. Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C. B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts. Cancer Chemother Pharmacol 2005;55:21-32.
10. Fortugno P, Beltrami E, Plescia J, Sessa WC, Altieri DC. Regulation of survivin function by Hsp90. Proc Natl Acad Sci USA 2003a;100:13791-6.
11. Fortugno P, Beltrami E, Plescia J, Fontana J, Pradhan D, Marchisio PC et al. Regulation of survivin function by Hsp90. Proc Natl Acad Sci USA 2003b;100:13791-6.
12. Frangov T, Gaľdarski R, Dimitrova V, Popov V, Grozeva K, Rusenov D. Prognostic factors for survival in primary liver cancer. Khirurgiia (Sofiia) 2007;6:36-9.
13. Gazitt Y, Kolaparthi V, Moncada K, Thomas C, Freeman J. Targeted therapy of human osteosarcoma with 17AAG or rapamycin: characterization of induced apoptosis and inhibition of mTOR and Akt/MAPK/Wnt pathways. Int J Oncol 2009;34:551-61.
14. Georgakis GV, Li Y, Younes A. The heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9. Br J Haematol 2006;135:68-71.
15. Goldstein I, Marcel V, Olivier M, Oren M, Rotter V, Hainaut P. Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies. Cancer Gene Ther 2011;18:2-11.
16. Gyurkocza B, Plescia J, Raskett CM, Garlick DS, Lowry PA, Carter BZ et al. Antileukemic activity of shepherdin and molecular diversity of Hsp90 inhibitors. J Natl Cancer Inst 2006;98:1068-77.
17. Hartl FU. Molecular chaperones in cellular protein folding. Nature 1996;381:571.
18. Itoh H, Ogura M, Komatsuda A, Wakui H, Miura AB, Tashima Y. A novel chaperone-activity-reducing mechanism of the 90-kDa molecular chaperone HSP90. Biochem J 1999;343:697703.
19. Kaelin Jr WG. Taking aim at novel molecular targets in cancer therapy. J Clin Invest 1999;104:1495.
20. Kaur KG, Belotti D, Burger AM, Fisher-Nielson K, Borsotti P, Riccardi E et al. Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator. Clin Cancer Res 2004;10:4813-21.
21. Lang SA, Moser C, Gaumann A, Klein D, Glockzin G, Popp FC et al. Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin- 6/signal-transducer and activator of transcription 3/hypoxia- inducible factor-1A autocrine loop, and reduces orthotopic tumor growth. Clin Cancer Res 2007;13:6459-68.
22. Lee CL, Hsiao HH, Lin CW, Wu SP, Huang SY, Wu CY et al. Strategic shotgun proteomics approach for efficient construction of an expression map of targeted protein families in hepatoma cell lines. Proteomics 2003;3:2472-86.
23. Maillard E. Epidemiology, natural history and pathogenesis of hepatocellular carcinoma. Cancer Radiother 2011;15:3-6.
24. Mi J, Zhang X, Rabbani ZN, Liu Y, Su Z, Vujaskovic Z et al. H1 RNA polymerase III promoter-driven expression of an RNA aptamer leads to high-level inhibition of intracellular protein activity. Nucleic Acids Res 2006;34:3577-84.
25. Obermann WM, Sondermann H, Russo AA, Pavletich NP, Hartl FU. In vivo function of Hsp90 is dependent on ATP binding and ATP hydrolysis. J Cell Biol 1998;143:901-10.
26. Otaki M, Hatano M, Kobayashi K, Ogasawara T, Kuriyama T, Tokuhisa T. Cell cycle-dependent regulation of TlAP/m-survivin expression. Biochim Biophys Acta 2000;149:188-94.
27. RosenhagenMC, SōtiC, Schmidt U, WochnikGM, HartlFU, Holsboer F etal. The heat shock protein 90-targeting drug cisplatin selectively inhibits steroid receptor activation. Mol Endocrinol 2003;17:1991-2001.
28. Sah NK, Khan Z, Khan GJ, Bisen PS. Structural, functional and therapeutic biology of survivin. Cancer Lett 2006;244:164-71.
29. Sharp S, Workman P. Inhibitors of the HSP90 molecular chaperone: current status. Adv Cancer Res 2006;95:323-48
30. 17-AAG sensitized malignant glioma cells to death-receptor mediated apoptosis
31. Smith V, Sausville EA, Camalier RF, Fiebig HH, Burger AM. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models. Cancer Chemother Pharmacol 2005;56:126-37.
32. Stingl L, Stü hmer T, Chatterjee M, Jensen MR, Flentje M, Djuzenova CS. Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction. Br J Cancer 2010;102:1578-91.
33. Tommasi S, Pinto R, Pilato B, Paradiso A. Molecular pathways and related target therapies in liver carcinoma. Curr Pharm Des 2007;13:3279-87.
34. Vaseva AV, Yallowitz AR, Marchenko ND, Xu S, Moll UM. Blockade of Hsp90 by 17AAG antagonizes MDMX and synergizes with Nutlin to induce p53-mediated apoptosis in solid tumors. Cell Death Dis 2011;2:e156.
35. Workman P, Burrows F, Neckers L, Rosen N. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann NY Acad Sci 2007;1113:202-16.
36. Xu AG, Yu ZJ, Jiang B, Wang XY, Zhong XH, Liu JH et al. Colorectal cancer in Guangdong Province of China: a demographic and anatomic survey. World J Gastroenterol 2010;16:960-5.
37. Zhang X, Li Y, Huang Q, Wang H, Yan B, Dewhirst MW, Li CY. Increased resistance of tumor cells to hyperthermia mediated by integrinlinked kinase. Clin Cancer Res 2003;9:1155-60.